Can domperidone decrease transit time of pediatric video capsule endoscopy? A randomized controlled trial

Area of Science:

• Pediatric Gastroenterology
• Medical Devices
• Pharmacology

Background:

• Reduced gastric transit time (GTT) and small bowel transit time (SBTT) can improve video capsule endoscopy (VCE) complete examination rates.
• Investigating prokinetic agents is crucial for optimizing VCE procedures in children.

Purpose of the Study:

• To evaluate the efficacy of domperidone in reducing GTT and SBTT in pediatric patients undergoing VCE.
• To determine if domperidone improves the complete examination rate of VCE in this population.

Main Methods:

• A single-center randomized controlled trial (RCT) involving 200 pediatric patients was conducted.
• Patients were randomized to receive either domperidone or a placebo.
• Primary outcomes included GTT and SBTT; the secondary outcome was the VCE complete examination rate. Safety outcomes were also monitored.

Main Results:

• No significant differences in median GTT or SBTT were observed between the domperidone and control groups.
• The complete examination rates were high and similar in both groups (97% vs. 98%).
• Domperidone was found to be safe with no significant adverse effects reported.

Conclusions:

• Domperidone does not effectively reduce GTT or SBTT in pediatric patients undergoing VCE.
• The use of domperidone does not enhance the complete examination rate for VCE in children.
• Further research may explore alternative prokinetic agents or strategies to improve VCE outcomes in pediatric populations.